The Schousboe study has important public policy implications. Even though the Surgeon General has highlighted the fact that osteoporosis is a significant health problem in men, very little bone mineral density (BMD) testing is currently done in men. The International Society of Clinical Densitometry (ISCD) has published guidelines for BMD testing in men, but very few men receive this service. It is hoped that this study will increase physician's use of appropriate BMD testing in men and spur public policy towards universally mandated reimbursement for BMD testing in older men, similar to what exists now for women.

Another factor that may help increase the treatment of male osteoporosis is the fact that alendronate (including Merck’s Fosamax), the most popular bisphosphonate for the treatment of osteoporosis, will likely be available in generic form in 2008.

Hologic Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic is the recognized leader in the development and commercialization of computer-aided detection (CAD), an innovative technology that assists physicians in the earlier detection of breast cancer. For more information, visit www.hologic.com.

This release contains forward-looking information that involves risks and uncertainties, including statements regarding Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding purchases of Hologic’s products, including any implication of future revenues from existing orders or any implication of future orders. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. In certain circumstances, orders may be canceled or rescheduled by customers without significant penalty. Therefore, orders as of any particular date should not be relied upon as indicative of Hologic’s net revenues for any future period. Other factors that could adversely affect the Company’s business and prospects are described in the Company’s filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based.